Back to search results

Digital Monitoring of Huntington's Disease Symptoms

This study is looking at new ways to track Huntington's Disease (HD) symptoms using wearable sensors and other digital health tools. Researchers want to see if these tools can accurately measure changes in daily walking and how often people sit down and stand up over 12 months. You might be able to join if you are between 25 and 65 years old, have a genetic diagnosis of HD, can walk without help, and speak English. The study is observational, meaning you won't receive a specific treatment, but researchers will gather information about your disease.

Study design
This is an observational study with a planned enrollment of 75 participants. It is not specified if it is randomized or blinded.
What's involved
You would participate in 5 study visits over approximately 12 months, occurring every 3 months. During visits, you will complete questionnaires, clinical assessments, and digital assessments (speech, cognitive, motor, and finger tapping).
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 months, with primary measurements taken at the 12-month mark.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07315984

Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease

Not Yet Recruiting
Not specifiedAges 25–65Observational
BioSensics
~75 participants
Updated 2026-01-05 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in daily walking duration during activities of daily living from baseline to 12 months as measured by the PAMSys pendant
Measured over 12 months
+1 more outcome measured

Conditions

Huntington Disease

Explore related trials

Huntington's DiseaseHTT Gene

NCT07315984

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Rochester Medical Center

    Rochester, New Yorkstudy coordinator listed

  • Vanderbilt University Medical Center

    Nashville, Tennesseeno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Ana Enriquez
[email protected]
888-589-6213 · ext. 502
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female, aged 25-65 years
For HD participants: Genetically diagnosed with HD
Fluent in English (able to speak and read).
Ambulatory without the need for a walking aid.
Able to independently perform all study activities safely, as determined by the investigator.
Willing and able to provide informed consent and comply with all study procedures.
Male or female, aged 25-65 years
Clinically assessed to be in good health, with no evidence of neurological disorders that could cause involuntary movements or gait disturbances

Exclusion

Diagnosis of juvenile-onset HD.
Individuals who are non-ambulatory.
Individuals with a neurological, medical, or psychiatric condition that, in the investigator's judgment, would interfere with safe participation in study activities.
Montreal Cognitive Assessment (MoCA) score of 18 or lower
Pregnant individuals, due to potential changes in gait and physical activity during pregnancy.
Cannot be enrolled into a blinded intervention trial at baseline.

What this trial measures

  • Change in daily walking duration during activities of daily living from baseline to 12 months as measured by the PAMSys pendant12 months

    Daily walking duration (hours) will be measured by the PAMSys pendant. PAMSys is a FDA-listed Class II wearable device for measuring physical activity and posture during activities of daily living. PAMSys will be worn for 1 week after the baseline, 3 month, 6 month, 9 month, and 12 month visits.

  • Change in daily number of sit to stand transitions (count) during activities of daily living from baseline to 12 months as measured by the PAMSys pendant.12 months

    Daily number of sit to stand transitions will be measured by the PAMSys pendant. PAMSys is a FDA-listed Class II wearable device for measuring physical activity and posture during activities of daily living. PAMSys will be worn for 1 week after the baseline, 3 month, 6 month, 9 month, and 12 month visits.